Rational design of DNA vaccines for the induction of human papillomavirus type 16 E6- and E7-specific cytotoxic T-cell responses
Many DNA vaccine candidates have been developed for the treatment of human papillomavirus type 16 (HPV16)-induced malignancies. Most of these vaccines consist of a fusion of E7 with a "carrier-protein" that functions to increase the potency of the vaccine. The nature of these carrier-prote...
Gespeichert in:
| Veröffentlicht in: | Human gene therapy Jg. 23; H. 12; S. 1301 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
01.12.2012
|
| Schlagworte: | |
| ISSN: | 1557-7422, 1557-7422 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Many DNA vaccine candidates have been developed for the treatment of human papillomavirus type 16 (HPV16)-induced malignancies. Most of these vaccines consist of a fusion of E7 with a "carrier-protein" that functions to increase the potency of the vaccine. The nature of these carrier-proteins varies widely, and the mechanisms proposed to explain the enhanced immunogenicity of such fusions are often linked to the biological function of the carrier-protein. However, the potentiating effect of these carrier-proteins might also be explained by more general mechanisms, such as the provision of CD4+ T-cell help, increased antigen stability, or altered subcellular localization of the antigen. To assess whether these more generic mechanisms could suffice to generate highly immunogenic DNA vaccines, we evaluated a series of modular HPV16 E7 DNA vaccines in which the presence of CD4+ T-cell help, the presence of an endogenous carrier-protein, and the subcellular localization of the antigen could be systematically altered. Using this approach, we demonstrate that the addition of an element that provides CD4+ T-cell help, elements that enforce endoplasmic reticulum (ER) localization/retention are both necessary and sufficient to create markedly effective HPV16 E7-directed DNA vaccines. Importantly, the resulting design rules also apply to an HPV16 E6-directed DNA vaccine. The developed "HELP(ER)" HPV DNA vaccines encode only very limited additional sequences besides the antigen, thereby reducing the risk of antigenic competition and/or autoimmunity. |
|---|---|
| AbstractList | Many DNA vaccine candidates have been developed for the treatment of human papillomavirus type 16 (HPV16)-induced malignancies. Most of these vaccines consist of a fusion of E7 with a "carrier-protein" that functions to increase the potency of the vaccine. The nature of these carrier-proteins varies widely, and the mechanisms proposed to explain the enhanced immunogenicity of such fusions are often linked to the biological function of the carrier-protein. However, the potentiating effect of these carrier-proteins might also be explained by more general mechanisms, such as the provision of CD4+ T-cell help, increased antigen stability, or altered subcellular localization of the antigen. To assess whether these more generic mechanisms could suffice to generate highly immunogenic DNA vaccines, we evaluated a series of modular HPV16 E7 DNA vaccines in which the presence of CD4+ T-cell help, the presence of an endogenous carrier-protein, and the subcellular localization of the antigen could be systematically altered. Using this approach, we demonstrate that the addition of an element that provides CD4+ T-cell help, elements that enforce endoplasmic reticulum (ER) localization/retention are both necessary and sufficient to create markedly effective HPV16 E7-directed DNA vaccines. Importantly, the resulting design rules also apply to an HPV16 E6-directed DNA vaccine. The developed "HELP(ER)" HPV DNA vaccines encode only very limited additional sequences besides the antigen, thereby reducing the risk of antigenic competition and/or autoimmunity. Many DNA vaccine candidates have been developed for the treatment of human papillomavirus type 16 (HPV16)-induced malignancies. Most of these vaccines consist of a fusion of E7 with a "carrier-protein" that functions to increase the potency of the vaccine. The nature of these carrier-proteins varies widely, and the mechanisms proposed to explain the enhanced immunogenicity of such fusions are often linked to the biological function of the carrier-protein. However, the potentiating effect of these carrier-proteins might also be explained by more general mechanisms, such as the provision of CD4+ T-cell help, increased antigen stability, or altered subcellular localization of the antigen. To assess whether these more generic mechanisms could suffice to generate highly immunogenic DNA vaccines, we evaluated a series of modular HPV16 E7 DNA vaccines in which the presence of CD4+ T-cell help, the presence of an endogenous carrier-protein, and the subcellular localization of the antigen could be systematically altered. Using this approach, we demonstrate that the addition of an element that provides CD4+ T-cell help, elements that enforce endoplasmic reticulum (ER) localization/retention are both necessary and sufficient to create markedly effective HPV16 E7-directed DNA vaccines. Importantly, the resulting design rules also apply to an HPV16 E6-directed DNA vaccine. The developed "HELP(ER)" HPV DNA vaccines encode only very limited additional sequences besides the antigen, thereby reducing the risk of antigenic competition and/or autoimmunity.Many DNA vaccine candidates have been developed for the treatment of human papillomavirus type 16 (HPV16)-induced malignancies. Most of these vaccines consist of a fusion of E7 with a "carrier-protein" that functions to increase the potency of the vaccine. The nature of these carrier-proteins varies widely, and the mechanisms proposed to explain the enhanced immunogenicity of such fusions are often linked to the biological function of the carrier-protein. However, the potentiating effect of these carrier-proteins might also be explained by more general mechanisms, such as the provision of CD4+ T-cell help, increased antigen stability, or altered subcellular localization of the antigen. To assess whether these more generic mechanisms could suffice to generate highly immunogenic DNA vaccines, we evaluated a series of modular HPV16 E7 DNA vaccines in which the presence of CD4+ T-cell help, the presence of an endogenous carrier-protein, and the subcellular localization of the antigen could be systematically altered. Using this approach, we demonstrate that the addition of an element that provides CD4+ T-cell help, elements that enforce endoplasmic reticulum (ER) localization/retention are both necessary and sufficient to create markedly effective HPV16 E7-directed DNA vaccines. Importantly, the resulting design rules also apply to an HPV16 E6-directed DNA vaccine. The developed "HELP(ER)" HPV DNA vaccines encode only very limited additional sequences besides the antigen, thereby reducing the risk of antigenic competition and/or autoimmunity. |
| Author | Aleyd, Esil Schumacher, Ton N Haanen, John B Oosterhuis, Koen Vrijland, Kim |
| Author_xml | – sequence: 1 givenname: Koen surname: Oosterhuis fullname: Oosterhuis, Koen organization: Division of Immunology, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands – sequence: 2 givenname: Esil surname: Aleyd fullname: Aleyd, Esil – sequence: 3 givenname: Kim surname: Vrijland fullname: Vrijland, Kim – sequence: 4 givenname: Ton N surname: Schumacher fullname: Schumacher, Ton N – sequence: 5 givenname: John B surname: Haanen fullname: Haanen, John B |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22971245$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkEtPwzAQhC1URB9w44x85BKwN7UdH6tSHlIFEirnyLEdapTYIU4qeuOnk4oicdpZ7aed0UzRyAdvEbqk5IaSTN5u-_oGCIVhoydoQhkTiZgDjP7pMZrG-EEITRkXZ2gMIAWFOZug71fVueBVhY2N7t3jUOK75wXeKa2dtxGXocXd1mLnTa8P6IEYPJXHjWpcVYVa7VzbR9ztG4spxyueYOUNXokkNla70mms913owtegNom2VYVbG5vgo43n6LRUVbQXxzlDb_erzfIxWb88PC0X60SnjHVJwZmgGRib8rRIC9CcybkpDeGMU1DDgTMoM2kJp0aC4sIIQTKlQc8zmTGYoevfv00bPnsbu7x28RBFeRv6mFNIJWGMpnJAr45oX9TW5E3ratXu87_W4Aelim-e |
| CitedBy_id | crossref_primary_10_1002_ijc_30679 crossref_primary_10_1158_2326_6066_CIR_17_0408 crossref_primary_10_1159_000537896 crossref_primary_10_1007_s12192_018_0952_8 crossref_primary_10_4161_hv_26088 crossref_primary_10_4049_jimmunol_1901410 crossref_primary_10_1111_imcb_12650 crossref_primary_10_1158_2326_6066_CIR_18_0654 crossref_primary_10_1038_s41392_023_01471_y crossref_primary_10_1038_gt_2015_24 crossref_primary_10_1136_jitc_2021_002547 crossref_primary_10_3389_fimmu_2020_592569 crossref_primary_10_1007_s00262_017_2006_y crossref_primary_10_1016_j_virusres_2016_11_023 crossref_primary_10_1038_gt_2013_81 crossref_primary_10_1007_s00262_018_2276_z crossref_primary_10_1186_s40001_023_01241_0 crossref_primary_10_1038_s41590_019_0404_3 crossref_primary_10_1080_1061186X_2022_2107651 crossref_primary_10_1038_s41467_019_13438_1 crossref_primary_10_1084_jem_20191711 crossref_primary_10_1177_2515135519874677 crossref_primary_10_1089_nat_2017_0717 crossref_primary_10_1016_j_vaccine_2016_08_039 crossref_primary_10_1038_s41577_018_0044_0 crossref_primary_10_3390_pharmaceutics14091861 crossref_primary_10_1016_j_imlet_2025_107022 crossref_primary_10_1158_0008_5472_CAN_15_3130 crossref_primary_10_1080_1061186X_2021_1919124 crossref_primary_10_1016_j_omton_2024_200835 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1089/hum.2012.101 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1557-7422 |
| ExternalDocumentID | 22971245 |
| Genre | Journal Article |
| GroupedDBID | --- .55 .GJ 0R~ 29I 34G 39C 4.4 53G 5GY 5RE ABBKN ABJNI ACGFO ACGFS ACIWK ACPRK ADBBV AENEX AFRAH ALMA_UNASSIGNED_HOLDINGS BNQNF CAG CGR COF CS3 CUY CVF DU5 EBS ECM EIF EJD F5P IAO IER IGS IH2 IHR ITC L7B MV1 NPM NQHIM O9- P2P R.V RIG RML RMSOB UE5 X7M Y6R ZGI ZXP 7X8 SCNPE |
| ID | FETCH-LOGICAL-c355t-b657182de363b3b2c6594dfd065612a2de652f89e061d92a67d7708ac2c489852 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 32 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000312439800009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1557-7422 |
| IngestDate | Thu Sep 04 15:37:46 EDT 2025 Mon Jul 21 06:03:55 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c355t-b657182de363b3b2c6594dfd065612a2de652f89e061d92a67d7708ac2c489852 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 22971245 |
| PQID | 1239055139 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1239055139 pubmed_primary_22971245 |
| PublicationCentury | 2000 |
| PublicationDate | 2012-12-01 |
| PublicationDateYYYYMMDD | 2012-12-01 |
| PublicationDate_xml | – month: 12 year: 2012 text: 2012-12-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Human gene therapy |
| PublicationTitleAlternate | Hum Gene Ther |
| PublicationYear | 2012 |
| SSID | ssj0013567 |
| Score | 2.2159798 |
| Snippet | Many DNA vaccine candidates have been developed for the treatment of human papillomavirus type 16 (HPV16)-induced malignancies. Most of these vaccines consist... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1301 |
| SubjectTerms | Animals CD4-Positive T-Lymphocytes - immunology Cell Line Drug Design Endoplasmic Reticulum - metabolism Female Human papillomavirus 16 - immunology Humans Male Mice Mice, Inbred C57BL Oncogene Proteins, Viral - genetics Oncogene Proteins, Viral - immunology Papillomavirus E7 Proteins - genetics Papillomavirus E7 Proteins - immunology Papillomavirus Infections - prevention & control Papillomavirus Vaccines - genetics Papillomavirus Vaccines - immunology Recombinant Proteins - genetics Recombinant Proteins - immunology Repressor Proteins - genetics Repressor Proteins - immunology T-Lymphocytes, Cytotoxic - immunology Uterine Cervical Neoplasms - prevention & control Uterine Cervical Neoplasms - virology Vaccines, DNA - genetics Vaccines, DNA - immunology |
| Title | Rational design of DNA vaccines for the induction of human papillomavirus type 16 E6- and E7-specific cytotoxic T-cell responses |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/22971245 https://www.proquest.com/docview/1239055139 |
| Volume | 23 |
| WOSCitedRecordID | wos000312439800009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8QwFA7ueHHfF57gNVjTZjuJ6IgHHUQU5jZkGxzQdpzODHrzp_vSVvQiCF5KISmE5PW97235CDkOKkOjiE4Os0zSTItArZMcZZkhPLFC2rRqFL6R7bbqdPRdE3Arm7LKL51YKWpfuBgjP0ENq5PIRqLPBq80skbF7GpDoTFNZlMciVItOz-yCLxikEWTKSm6gKwpfE-UPnkaxzb0Uxa919_BZWVkrpb_u7wVstTASziv5WGVTIV8jczXhJPva2Thtkmlr5OP-yYMCL4q4oCiB5ftc5gYFyeUgGgWEB0COu31DbNxRkXpBwMz6D8_Fy9m0h-OS4hhXDgV0BIUTO6hJWls4IxFSODeR8WoeMO3BxqTBDCsi3JDuUEer1oPF9e0oWOgDkHJiFrB0ZAxH1KR2tQyJ7jOfM8jiEGYZHBAcNZTOiBE8JoZIb2UiTKOuUxpxdkmmcmLPGwT8DZNvGHKIrhEl4srZyz3OlVMZ86LZIccfe1yF8U9Ls_koRiX3e993iFb9VF1B_W9HF3GtES4wnf_8PUeWYzHXxem7JPZHv7s4YDMucmoXw4PKznCZ_vu9hNpj9Co |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rational+design+of+DNA+vaccines+for+the+induction+of+human+papillomavirus+type+16+E6-+and+E7-specific+cytotoxic+T-cell+responses&rft.jtitle=Human+gene+therapy&rft.au=Oosterhuis%2C+Koen&rft.au=Aleyd%2C+Esil&rft.au=Vrijland%2C+Kim&rft.au=Schumacher%2C+Ton+N&rft.date=2012-12-01&rft.eissn=1557-7422&rft.volume=23&rft.issue=12&rft.spage=1301&rft_id=info:doi/10.1089%2Fhum.2012.101&rft_id=info%3Apmid%2F22971245&rft_id=info%3Apmid%2F22971245&rft.externalDocID=22971245 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1557-7422&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1557-7422&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1557-7422&client=summon |